SuperworthStaar Surgical STAA
- Market cap
- $1.1B
- PE
- 323×
- 8y median 143×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.3×
- EV/EBIT
- 57.7×
- Revenue, 12 months
- $339.6M
- +51% on a year ago
- Net margin
- 1.1%
- Free cash flow yield
- −0.6%
Staar Surgical trades at 323× trailing earnings, pricier than 82% of the last ten years. Revenue was $339.6M over the last twelve months, up 51% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $80.3M+6% | $76.3M+19% | $77.4M+5% | $99M+7% | $88.6M+10% | $49M−36% | $42.6M−45% | $44.3M−55% | $94.7M+7% | $57.8M+18% | $93.5M+120% | $93.5M+111% | |
| Cost of revenue | $16.7M+7% | $15.5M+9% | $16.3M+2% | $20.6M−5% | $20.1M+21% | $17.3M+11% | $14.6M−11% | $11.5M−44% | $16.9M−16% | $14.1M−19% | $24.7M+69% | $23.8M+107% |
| Gross profit | $63.6M+5% | $60.7M+22% | $61M+6% | $78.4M+11% | $68.5M+8% | $31.6M−48% | $28M−54% | $32.8M−58% | $77.9M+14% | $43.7M+38% | $68.9M+146% | $69.7M+113% |
| R&D | $11.5M+19% | $10.9M+11% | $13.4M+30% | $11.9M+1% | $12.2M+7% | $9.8M−10% | $11.3M−15% | $10.3M−14% | $9.2M−25% | $9.2M−5% | $9.9M−13% | $9.9M−3% |
| SG&A | $57.3M+23% | $50.3M+3% | $63.3M+16% | $66.5M+7% | $62.8M+10% | $59.6M+18% | $85.4M+35% | $62.8M−6% | $59.4M−5% | $66.6M+12% | $60.9M−29% | $59.6M−5% |
| $6.3M−54% | $10.4M+979% | −$2.3M | $11.9M+38% | $5.7M−10% | −$27.9M | −$57.4M+2417% | −$30M | $18.5M+225% | −$22.8M−18% | $8M | $10.1M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $6.7M−46% | $13.7M+130% | −$2.2M | $10.3M+22% | $13.2M+95% | −$30.3M | −$54.5M+2364% | −$25.9M | $18.8M+43% | −$20.7M−32% | $8.2M | $11M |
| $1.9M−17% | $6M+4648% | $1.1M−44% | $3M+22% | $3.2M+65% | $3.9M−35% | −$275K | −$9.1M | $9.9M+212% | −$2.3M | $3M | $3M | |
| Net income | $4.8M−53% | $7.8M+33% | −$3.3M | $7.4M+22% | $10M+107% | −$34.2M | −$54.2M+1524% | −$16.8M | $8.9M−11% | −$18.3M−47% | $5.2M | $8.1M |
| $0.10−52% | $0.16+33% | −$0.07 | $0.15+25% | $0.20+100% | −$0.69 | −$1.10+1471% | −$0.34 | $0.18−10% | −$0.37−46% | $0.10 | $0.16 | |
| 49.4M−0% | 49.2M−0% | 48.9M−1% | 49.8M+1% | 49.7M+1% | 49.3M+0% | 49.3M+1% | 49.5M−1% | 50.5M+2% | 49.8M+1% | 50.9M+3% | 51.5M+4% |
Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
R&D: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
SG&A: Q1 FY10: 6 months less the 3 months printed beside them.
Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY10: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 8 periods, Q4 FY11 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Staar Surgical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| Peer median | $1.3B | 30.1× | 38.6× | 2.0× | +8% | 8.2% |
More on Staar Surgical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .